gabexate has been researched along with Cancer of Mouth in 2 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohkoshi, M | 2 |
| Oka, T | 1 |
1 review available for gabexate and Cancer of Mouth
| Article | Year |
|---|---|
[Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
Topics: Adenocarcinoma; Animals; Carcinoma, Lewis Lung; Carcinoma, Squamous Cell; Cell Division; Colonic Neo | 1995 |
1 other study available for gabexate and Cancer of Mouth
| Article | Year |
|---|---|
Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Esters; Evaluation Studies as Topic; Female; Gabexate; Guanidines; | 1984 |